Literature DB >> 12114682

Molecular Screening for RET Proto-Oncogene Mutations in a German MEN2A Pedigree.

Iris Wundrack, Jeannette Reichert, Heinz-Joachim Langer, Ernst Leicht, Marukke Herrmann, Frank Subke, Eckart Meese, Nikolaus Blin.   

Abstract

Multiple endocrine neoplasia type 2A (MEN2A), a dominantly inherited cancer syndrome, is defined by the presence of medullary thyroid carcinoma (MTC), pheochromocytoma (pheo), and primary hyperparathyroidism (p-HPT). Along with multiple endocrine neoplasia type 2B (MEN2B) and familial medullary thyroid carcinoma (FMTC), it is associated with germline mutations of the RETproto-oncogene localized in 10q11.2. In FMTC and MEN2A, point mutations result in the substitution of one of five Cys residues in the extracellular domain of RET. In a larger pedigree from Saarland, several individuals were observed with C-cell thyroid carcinoma. We screened 16 members of this extended family by single-strand conformation polymorphism analysis (SSCP), polymerase chain reaction (PCR), followed by restriction enzyme analysis, and by sequencing the mutated regions. In 7 family members, all of whom had been earlier operated on because of MTC, a DNA transition from T to C was observed, causing an amino acid substitution Cys(634)Arg. Nine members of the kindred did not carry the mutation and may be excluded from yearly biochemical testing. One of these persons seems to have been unnecessarily operated on owing to a borderline pentagastrin test.

Entities:  

Year:  1996        PMID: 12114682     DOI: 10.1007/bf02739917

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  18 in total

1.  An efficient salt-chloroform extraction of DNA from blood and tissues.

Authors:  R Müllenbach; P J Lagoda; C Welter
Journal:  Trends Genet       Date:  1989-12       Impact factor: 11.639

2.  Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group.

Authors:  C G Mathew; D F Easton; Y Nakamura; B A Ponder
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

3.  RET proto-oncogene mutations in French MEN 2A and FMTC families.

Authors:  I Schuffenecker; M Billaud; A Calender; B Chambe; N Ginet; C Calmettes; E Modigliani; G M Lenoir
Journal:  Hum Mol Genet       Date:  1994-11       Impact factor: 6.150

4.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

Review 5.  Management of individual tumor syndromes. Medullary thyroid carcinoma and hyperparathyroidism.

Authors:  K J Snow; A E Boyd
Journal:  Endocrinol Metab Clin North Am       Date:  1994-03       Impact factor: 4.741

6.  Improved predictive test for MEN2, using flanking dinucleotide repeats and RFLPs.

Authors:  J R Howe; T C Lairmore; S K Mishra; S Dou; R Veile; S A Wells; H Donis-Keller
Journal:  Am J Hum Genet       Date:  1992-12       Impact factor: 11.025

7.  Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease.

Authors:  G Romeo; P Ronchetto; Y Luo; V Barone; M Seri; I Ceccherini; B Pasini; R Bocciardi; M Lerone; H Kääriäinen
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

8.  Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret.

Authors:  A Schuchardt; V D'Agati; L Larsson-Blomberg; F Costantini; V Pachnis
Journal:  Nature       Date:  1994-01-27       Impact factor: 49.962

9.  Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.

Authors:  K M Carlson; S Dou; D Chi; N Scavarda; K Toshima; C E Jackson; S A Wells; P J Goodfellow; H Donis-Keller
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  Germline mutations of the RET proto-oncogene in eight Japanese patients with multiple endocrine neoplasia type 2A (MEN2A).

Authors:  S Takiguchi-Shirahama; K Koyama; A Miyauchi; T Wakasugi; S Oishi; H Takami; K Hikiji; Y Nakamura
Journal:  Hum Genet       Date:  1995-02       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.